Kancera reports that the FRACTAL-study is on track to report top line results in Q3 2023
Kancera AB (publ) reports that 63 subjects have been recruited to the ongoing FRACTAL-study, a phase IIa study of KAND567 in myocardial infarction patients, which exceeds the initial objective of 60 study subjects in total. Kancera has previously announced...
Read More